Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease

Byoung Dae Lee, Joo Ho Shin, Jackalina Vankampen, Leonard Petrucelli, Andrew B. West, Han Seok Ko, Yun Il Lee, Kathleen A. Maguire-Zeiss, William J. Bowers, Howard J. Federoff, Valina L. Dawson, Ted M. Dawson

Research output: Contribution to journalArticle

251 Scopus citations

Abstract

Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)998-1000
Number of pages3
JournalNature Medicine
Volume16
Issue number9
DOIs
StatePublished - Sep 1 2010

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Lee, B. D., Shin, J. H., Vankampen, J., Petrucelli, L., West, A. B., Ko, H. S., Lee, Y. I., Maguire-Zeiss, K. A., Bowers, W. J., Federoff, H. J., Dawson, V. L., & Dawson, T. M. (2010). Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 16(9), 998-1000. https://doi.org/10.1038/nm.2199